- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Steven D. Shapiro, MD, Opines on the Benefits and Risks of Hospitals as Health Insurers
Steven D. Shapiro, MD, executive vice president, chief medical and science officer, University of Pittsburgh Medical Center, says healthcare reform's biggest benefit is that it is leading care from a system that is volume based to one that is value based.
Steven D. Shapiro, MD, executive vice president, chief medical and science officer, University of Pittsburgh Medical Center, says healthcare reform’s biggest benefit is that it is leading care from a system that is volume based to one that is value based.
“As we move from being paid more to do more and filling beds in hospitals, to managing premium, the advantage of understanding population health—either to have a different relationship with an insurer or to be an insurer oneself—can only be good in a new world.”
He suggests it is difficult to change the existing culture of many hospitals. In order to do so, there must be an appropriate infrastructure to support population health management.
Dr Shapiro adds that the University of Pittsburgh Medical Center’s main focus is quality. In using analytics, they are able study pathways and reduce variation in care, therefore becoming more efficient at lowering costs while improving quality.
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
